Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Ernexa Therapeutics Q3 2026 Results: Net Loss of $2.94M, Loss Widens

Ernexa Therapeutics reported a net loss of $12.5 million for the nine months ended September 30, 2026, which included a $2.0 million goodwill impairment charge. The company strengthened its cash position to $5.6 million through public offerings and ATM stock issuances, while research and development expenses nearly doubled compared to the prior year.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Profit before tax-2.9-1.2
Net income-2.9-1.2
EPS (diluted, $ a share)$-1.89$-3.77

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: ERNA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Ernexa Therapeutics Inc.: key numbers

Share price
$1.63Close, Nov 17
Market cap
$2.76M
Shares outstanding
1.69MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Ernexa Therapeutics Inc.

All →
5:26 PM ET 8-K
Investor Presentation

Ernexa Therapeutics Investor Presentation

Ernexa Therapeutics Inc. has made available a formal investor presentation for October 2026. The presentation is intended to provide strategic updates and company information to investors and is accessible via the company's investor relations website.

5:31 PM ET 8-K
Investor Presentation

Ernexa Therapeutics Investor Presentation

Ernexa Therapeutics Inc. has made available a new corporate fact sheet and a formal investor presentation for September 2026. The materials, filed under Item 7.01, provide updated corporate information and strategic highlights for investors and are accessible via the company's investor relations website.

4:51 PM ET 8-K
Leadership Change

Ernexa Therapeutics Leadership Change

Ernexa Therapeutics Inc. appointed Robert J. Spiegel, M.D. to its Board of Directors, effective September 14, 2026. Dr. Spiegel will be compensated according to the company's existing Board of Directors Compensation Plan and will serve until his successor is elected.

Counterparty
Robert J. Spiegel, M.D.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.